Trial Profile
Defining Reversal of Keloid Lesions by Th2 Targeting With Dupilumab Treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Keloids
- Focus Therapeutic Use
- 31 Jul 2023 Planned End Date changed from 31 Dec 2023 to 1 Jan 2025.
- 31 Jul 2023 Planned primary completion date changed from 31 Dec 2023 to 1 Jul 2024.
- 09 Aug 2021 New trial record